{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:05:57Z","timestamp":1790208357101,"version":"4.1.0"},"reference-count":78,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Hepatitis C virus (HCV) is a major health problem in hemodialysis patients, which leads to significant morbidity and mortality through progressive hepatic fibrosis or cirrhosis. Percutaneous liver biopsy is the gold standard to stage hepatic fibrosis. However, it is an invasive procedure with postbiopsy complications. Because uremia may significantly increase the risk of fatal and nonfatal bleeding events, the use of noninvasive means to assess the severity of hepatic fibrosis is particularly appealing to hemodialysis patients. To date, researchers have evaluated the performance of various biochemical, serological, and radiological indices for hepatic fibrosis in hemodialysis patients with HCV infection. In this review, we will summarize the progress of noninvasive indices for assessing hepatic fibrosis and propose a pragmatic recommendation to diagnose the stage of hepatic fibrosis with a noninvasive index, in hemodialysis patients with HCV infection.<\/jats:p>","DOI":"10.3390\/diagnostics12102282","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T21:22:23Z","timestamp":1663795343000},"page":"2282","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-9707","authenticated-orcid":false,"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei 100225, Taiwan"},{"name":"Hepatitis Research Center, National Taiwan University Hospital, Taipei 100225, Taiwan"},{"name":"Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou 640203, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei 100225, Taiwan"},{"name":"Hepatitis Research Center, National Taiwan University Hospital, Taipei 100225, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100233, Taiwan"},{"name":"Department of Medical Research, National Taiwan University Hospital, Taipei 100225, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","article-title":"Treatment of hepatitis C virus infection in patients with end-stage renal disease","volume":"26","author":"Liu","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","article-title":"Hepatitis C virus and the kidney","volume":"15","author":"Pol","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liu, C.-H., and Kao, J.-H. (2022). Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. Hepatol. Int.","DOI":"10.1007\/s12072-022-10390-z"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","author":"Goodkin","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.2215\/CJN.00410111","article-title":"Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis","volume":"6","author":"Gordon","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/apt.16697","article-title":"Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment","volume":"55","author":"Liu","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2113","DOI":"10.1097\/MD.0000000000002113","article-title":"Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: An 8-year nationwide cohort study in Taiwan","volume":"94","author":"Hsu","year":"2015","journal-title":"Medicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2017.12.003","article-title":"Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis","volume":"68","author":"Millbourn","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4318\/tjg.2009.0020","article-title":"The quality of life in hemodialysis patients with chronic hepatitis C virus infection","volume":"20","author":"Demir","year":"2009","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1038\/s41598-020-66182-8","article-title":"Elbasvir\/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/gutjnl-2020-323569","article-title":"Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"71","author":"Liu","year":"2022","journal-title":"Gut"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/liv.14363","article-title":"Micro-elimination of hepatitis C virus","volume":"40","author":"Hollande","year":"2020","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Wong","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kim, N.J., Vutien, P., Cleveland, E., Cravero, A., and Ioannou, G.N. (2022). Fibrosis stage-specific incidence of hepatocellular cancer after hepatitis C cure with direct-acting antivirals: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol.","DOI":"10.1016\/j.cgh.2022.04.013"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1525-139X.2008.00556.x","article-title":"Treatment of bleeding in dialysis patients","volume":"22","author":"Galbusera","year":"2009","journal-title":"Semin. Dial."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.cgh.2007.07.010","article-title":"Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease","volume":"5","author":"Pawa","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00004836-200208000-00013","article-title":"Characteristics of hepatitis C in renal transplant candidates","volume":"35","author":"Cotler","year":"2002","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/0016-5085(90)91167-5","article-title":"A 21-year experience with major hemorrhage after percutaneous liver biopsy","volume":"99","author":"McGill","year":"1990","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(86)90883-4","article-title":"Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver","volume":"1","author":"Maharaj","year":"1986","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1572-0241.1998.044_c.x","article-title":"AST\/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection","volume":"93","author":"Sheth","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/15.10.1716","article-title":"The utility of AST\/ALT ratio as a non-invasive demonstration of the degree of liver fibrosis in chronic HCV patients on long-term haemodialysis","volume":"15","author":"Odemir","year":"2000","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cgh.2020.02.019","article-title":"Diagnostic accuracy of noninvasive tests to detect advanced hepatic fibrosis in patients with hepatitis C and end-stage renal disease","volume":"18","author":"Schmoyer","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.21681","article-title":"Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection","volume":"46","author":"Schiavon","year":"2007","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ki.2010.74","article-title":"The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C","volume":"78","author":"Liu","year":"2010","journal-title":"Kidney Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ndt\/gft485","article-title":"Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients?","volume":"29","author":"Jiang","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1097\/MEG.0000000000002031","article-title":"Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients","volume":"33","author":"Pestana","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lee, J.-J., Wei, Y.-J., Lin, M.-Y., Niu, S.-W., Hsu, P.-Y., Huang, J.-C., Jang, T.-Y., Yeh, M.-L., Huang, C.-I., and Liang, P.-C. (2020). The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0242601"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5455\/medarh.2012.66.226-230","article-title":"Indirect serum fibrosis markers in hepatitis C virus (HCV) infection","volume":"66","author":"Paunovic","year":"2012","journal-title":"Med. Arch."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcv.2005.09.010","article-title":"Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia","volume":"35","author":"Lopes","year":"2006","journal-title":"J. Clin. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest","volume":"46","author":"Mallet","year":"2007","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/MEG.0b013e32830dfcb3","article-title":"King\u2019s Score: An accurate marker of cirrhosis in chronic hepatitis C","volume":"21","author":"Cross","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_46","first-page":"77","article-title":"Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level","volume":"60","author":"Ohta","year":"2006","journal-title":"Acta Med. Okayama"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study","volume":"357","author":"Ratziu","year":"2001","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1373\/clinchem.2004.032227","article-title":"Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C","volume":"50","author":"Poynard","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/01.tp.0000183399.85804.02","article-title":"Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus","volume":"80","author":"Varaut","year":"2005","journal-title":"Transplantation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"c289","DOI":"10.1159\/000320751","article-title":"Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C","volume":"117","author":"Canbakan","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1365-2893.2008.00992.x","article-title":"Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection","volume":"15","author":"Schiavon","year":"2008","journal-title":"J. Viral Hepat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1413-8670(10)70071-4","article-title":"Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis","volume":"14","author":"Avila","year":"2010","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s11255-015-1017-x","article-title":"Serum hyaluronic acid in chronic viral hepatitis B and C: A biomarker for assessing liver fibrosis in chronic hemodialysis patients","volume":"47","author":"Sava","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_54","first-page":"71","article-title":"Inflammatory biomarkers and liver histopathology in non-uremic and uremic chronic hepatitis C patients","volume":"60","author":"Tatar","year":"2017","journal-title":"Acta Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18388\/abp.2016_1443","article-title":"The role of serum hyaluronic acid determination in the diagnosis of liver fibrosis","volume":"64","author":"Gudowska","year":"2017","journal-title":"Acta Biochim. Pol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1572-0241.2007.01761.x","article-title":"Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C","volume":"103","author":"Mehta","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_57","first-page":"1241","article-title":"Serum hyaluronic acid level does not reliably differentiate minimal and significant liver disease in chronic hepatitis C","volume":"32","author":"Arain","year":"2011","journal-title":"Saudi Med. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1440-1746.2000.02233.x","article-title":"Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group","volume":"15","author":"McHutchison","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10238-015-0388-8","article-title":"Hyaluronic acid concentration in liver diseases","volume":"16","author":"Gudowska","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0168-8278(00)80095-1","article-title":"Serum YKL-40 is increased in patients with hepatic fibrosis","volume":"32","author":"Johansen","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3748\/wjg.v11.i4.476","article-title":"Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease","volume":"11","author":"Saitou","year":"2005","journal-title":"World, J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cyto.2013.02.014","article-title":"YKL-40 in hemodialyzed patients with and without cardiovascular complications\u2014The enhancement by the coexistence of the seropositivity against hepatitis C virus infection","volume":"62","author":"Pawlak","year":"2013","journal-title":"Cytokine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Vergniol","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.04320510","article-title":"Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients","volume":"6","author":"Liu","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"46458","DOI":"10.1038\/srep46458","article-title":"Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population","volume":"7","author":"Cheng","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/hep.22007","article-title":"Acute viral hepatitis increases liver stiffness values measured by transient elastography","volume":"47","author":"Arena","year":"2008","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Giuffr\u00e8, M., Fouraki, S., Comar, M., Masutti, F., and Croc\u00e8, L.S. (2020). The importance of transaminases flare in liver elastography: Characterization of the probability of liver fibrosis overestimation by hepatitis C virus-induced cytolysis. Microorganisms, 8.","DOI":"10.3390\/microorganisms8030348"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40477-020-00456-9","article-title":"Alanine aminotransferase and spleno-portal dynamics affect spleen stiffness measured by point shear-wave elastography in patients with chronic hepatitis C in the absence of significant liver fibrosis","volume":"24","author":"Fouraki","year":"2021","journal-title":"J. Ultrasound"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2215\/CJN.01330308","article-title":"Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients","volume":"3","author":"Trevizoli","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1478-3231.2009.02100.x","article-title":"Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection","volume":"29","author":"Mederacke","year":"2009","journal-title":"Liver Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000439582","article-title":"Transient elastography in end-stage renal disease patients on hemodialysis: The effect of net fluid withdrawal","volume":"40","author":"Khunpakdee","year":"2015","journal-title":"Blood Purif."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1007\/s10620-017-4777-6","article-title":"Assessment of liver fibrosis by transient elastography should be done after hemodialysis in end stage renal disease patients with liver disease","volume":"62","author":"Taneja","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_74","first-page":"206","article-title":"Noninvasive fibrosis assessment in chronic viral hepatitis C associated with end stage renal disease","volume":"44","author":"Caragea","year":"2018","journal-title":"Curr. Health Sci. J."},{"key":"ref_75","first-page":"109","article-title":"Elastography: Where are we now?","volume":"67","author":"Colecchia","year":"2021","journal-title":"Minerva Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"key":"ref_77","first-page":"587","article-title":"Noninvasive assessment of fibrosis regression in hepatitis C virus sustained virologic responders","volume":"13","author":"Trivedi","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1111\/liv.15058","article-title":"Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease","volume":"41","author":"Broquetas","year":"2021","journal-title":"Liver Int."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/10\/2282\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:36:46Z","timestamp":1760143006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/10\/2282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":78,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["diagnostics12102282"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12102282","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}